In this episode of the Oncology Brothers podcast, we were joined by two international experts — Professor Gary Tse, a pathologist from the Chinese University of Hong Kong, and Dr. Carlos Barrios, a medical oncologist from Brazil — to unpack the evolving landscape of HER2 testing in breast cancer. What was once a binary positive or negative classification has now expanded to include HER2-low and HER2-ultra-low, opening the door to new treatment options for the majority of breast cancer patients.

Listen us on:

Follow us on social media:

Key topics discussed included:

Join us for this expert discussion on one of the most clinically impactful topics in breast oncology today. Don't forget to like, subscribe, and check out our other episodes for more insights on oncology!

#HER2, #BreastCancer, #BiomarkerTesting, #PrecisionOncology, #OncologyBrothers